Shanghai RAAS Blood Products Co Ltd Class A (002252) — Cash Flow Reinvestment Rate
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Cash Flow Reinvestment Rate of 0.41x as of March 2025, reinvesting CN¥317.67 Million (capex CN¥62.51 Million plus investments CN¥255.16 Million) from operating cash flow of CN¥775.56 Million. See 002252 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Shanghai RAAS Blood Products Co Ltd Class A Cash Flow Reinvestment Rate (2005–2023)
Historical reinvestment intensity for Shanghai RAAS Blood Products Co Ltd Class A across 18 annual periods. For the full cash flow conversion analysis, see Shanghai RAAS Blood Products Co Ltd Clas operating cash flow efficiency.
Annual Cash Flow Reinvestment Rate for Shanghai RAAS Blood Products Co Ltd Class A (2005–2023)
Year-by-year capital reinvestment analysis for Shanghai RAAS Blood Products Co Ltd Class A. See how financially flexible is Shanghai RAAS Blood Products Co Ltd Clas to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.49x | CN¥1.12 Billion | CN¥2.28 Billion | CN¥450.80 Million | ▼ -27.5% |
| 2022 | 0.68x | CN¥1.17 Billion | CN¥1.73 Billion | CN¥225.73 Million | ▲ +8.0% |
| 2021 | 0.63x | CN¥814.12 Million | CN¥1.29 Billion | CN¥204.61 Million | ▲ +17.7% |
| 2020 | 0.53x | CN¥624.78 Million | CN¥1.17 Billion | CN¥251.76 Million | ▲ +172.1% |
| 2019 | 0.20x | CN¥171.43 Million | CN¥872.69 Million | CN¥154.84 Million | ▼ -94.6% |
| 2018 | 3.66x | CN¥959.60 Million | CN¥262.50 Million | CN¥156.94 Million | ▼ -42.4% |
| 2017 | 6.35x | CN¥1.71 Billion | CN¥268.76 Million | CN¥157.84 Million | ▲ +273.3% |
| 2016 | 1.70x | CN¥1.08 Billion | CN¥638.22 Million | CN¥147.49 Million | ▲ +791.5% |
| 2015 | 0.19x | CN¥145.39 Million | CN¥762.42 Million | CN¥145.39 Million | ▲ +36.6% |
| 2014 | 0.14x | CN¥65.06 Million | CN¥465.96 Million | CN¥65.06 Million | ▼ -75.4% |
| 2012 | 0.57x | CN¥149.70 Million | CN¥263.46 Million | CN¥149.70 Million | ▼ -42.8% |
| 2011 | 0.99x | CN¥176.80 Million | CN¥178.03 Million | CN¥176.80 Million | ▲ +122.9% |
| 2010 | 0.45x | CN¥89.21 Million | CN¥200.21 Million | CN¥89.21 Million | ▼ -15.2% |
| 2009 | 0.53x | CN¥60.99 Million | CN¥116.01 Million | CN¥60.99 Million | ▲ +93.6% |
| 2008 | 0.27x | CN¥29.23 Million | CN¥107.64 Million | CN¥29.23 Million | ▲ +95.1% |
| 2007 | 0.14x | CN¥24.46 Million | CN¥175.71 Million | CN¥24.46 Million | ▼ -38.3% |
| 2006 | 0.23x | CN¥12.08 Million | CN¥53.58 Million | CN¥12.08 Million | ▼ -43.8% |
| 2005 | 0.40x | CN¥21.69 Million | CN¥54.02 Million | CN¥21.69 Million | — |